A Pharmacokinetic and Pharmacodynamic Study of Vincristine in Children With Leukemia
The pharmacokinetic behavior of vincristine in pediatric patients has not been well
characterized. The present study will obtain detailed information on vincristine
pharmacokinetics in patients being treated for standard risk ALL according to or on CCG
protocols 1952/1962/1991. A limited sampling strategy will be developed, and the
interpatient and intrapatient variability of vincristine pharmacokinetics in children will
be studied. A correlation between vincristine neurotoxicity and vincristine
pharmacokinetics will be sought.
Interventional
Endpoint Classification: Safety Study, Primary Purpose: Treatment
United States: Federal Government
980053
NCT00001689
January 1998
November 2003
Name | Location |
---|---|
National Cancer Institute (NCI) | Bethesda, Maryland 20892 |